Consun Pharmaceutical Group Limited
CPHGF
$1.08
$0.0747.34%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 13.04% | 10.74% | 6.91% | 6.14% | 5.35% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.04% | 10.74% | 6.91% | 6.14% | 5.35% |
| Cost of Revenue | 7.07% | 10.33% | 12.41% | 11.29% | 10.10% |
| Gross Profit | 15.11% | 10.88% | 5.12% | 4.46% | 3.79% |
| SG&A Expenses | 9.81% | 8.99% | 6.65% | 5.07% | 3.46% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 70.41% | -13.63% | -495.14% | -367.18% | -278.91% |
| Total Operating Expenses | 11.43% | 9.39% | 5.83% | 4.60% | 3.33% |
| Operating Income | 16.46% | 13.65% | 9.23% | 9.56% | 9.95% |
| Income Before Tax | 16.51% | 13.42% | 8.71% | 9.42% | 10.23% |
| Income Tax Expenses | 31.72% | 15.64% | -1.54% | 7.29% | 18.66% |
| Earnings from Continuing Operations | 15.03% | 13.20% | 9.81% | 9.63% | 9.47% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -245.29% | -165.97% | -74.44% | -101.10% | -175.32% |
| Net Income | 14.45% | 12.82% | 9.65% | 9.47% | 9.30% |
| EBIT | 16.46% | 13.65% | 9.23% | 9.56% | 9.95% |
| EBITDA | 13.38% | 11.70% | 8.50% | 8.59% | 8.72% |
| EPS Basic | 9.86% | 9.91% | 8.43% | 8.87% | 9.21% |
| Normalized Basic EPS | 11.04% | 10.02% | 7.45% | 8.69% | 9.97% |
| EPS Diluted | 9.33% | 9.27% | 7.82% | 8.07% | 8.31% |
| Normalized Diluted EPS | 10.63% | 9.34% | 6.62% | 7.70% | 8.94% |
| Average Basic Shares Outstanding | 3.82% | 2.43% | 1.04% | 0.54% | 0.04% |
| Average Diluted Shares Outstanding | 4.12% | 2.91% | 1.69% | 1.30% | 0.91% |
| Dividend Per Share | 36.82% | 100.26% | 280.00% | 559.41% | -- |
| Payout Ratio | 0.78% | 1.01% | 1.39% | 1.30% | 1.16% |